ADReCS

Pharmaceutical Information

Drug Name	Quinine
Drug ID	BADD_D01895
Description	An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Indications and Usage	For the treatment of malaria and leg cramps
Marketing Status	approved
ATC Code	P01BC01
DrugBank ID	DB00468
KEGG ID	D08460; D08461
MeSH ID	D011803
PubChem ID	3034034
TTD Drug ID	D03DDR
NDC Product Code	65162-811
UNII	A7V27PHC7A
Synonyms	Quinine \| Quinimax \| Quinine Bisulfate \| Bisulfate, Quinine \| Quinine Hydrochloride \| Hydrochloride, Quinine \| Myoquin \| Quinamm \| Quinbisan \| Legatrim \| Quinine Lafran \| Quinine Sulfate \| Sulfate, Quinine \| Quinine Sulphate \| Sulphate, Quinine \| Quinine-Odan \| Quinoctal \| Surquina \| Biquinate \| Strema \| Quindan \| Quinbisul \| Quinson \| Quinsul

Chemical Information

Molecular Formula	C20H24N2O2
CAS Registry Number	72402-53-0
SMILES	COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Suicide attempt	19.12.01.004	0.001101%
Supraventricular extrasystoles	02.03.03.011	-	-	Not Available
Syncope	02.11.04.015; 24.06.02.012; 17.02.04.008	-	-
Systemic lupus erythematosus	23.03.02.006; 15.06.02.003; 10.04.03.004	-	-	Not Available
Tachycardia	02.03.02.007	0.000734%		Not Available
Thrombocytopenia	01.08.01.002	0.007339%		Not Available
Thrombocytopenic purpura	23.06.01.007; 01.08.01.003	-	-	Not Available
Thrombotic microangiopathy	24.01.01.013; 20.01.07.004; 01.01.02.006	0.029722%		Not Available
Thrombotic thrombocytopenic purpura	24.07.06.014; 23.06.01.011; 01.08.01.005	0.000734%
Tinnitus	17.04.07.004; 04.04.01.002	0.003449%
Torsade de pointes	02.03.04.005	0.002202%		Not Available
Toxic epidermal necrolysis	23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006	-	-
Tremor	17.01.06.002	0.001468%
Tunnel vision	17.17.01.013; 06.02.07.005	0.000734%		Not Available
Urethral disorder	20.07.01.002	-	-	Not Available
Urinary tract disorder	20.08.01.001	-	-	Not Available
Urticaria	23.04.02.001; 10.01.06.001	-	-
Vasodilatation	24.03.02.003; 23.06.05.006	-	-	Not Available
Ventricular arrhythmia	02.03.04.006	0.001101%
Ventricular extrasystoles	02.03.04.007	-	-	Not Available
Ventricular fibrillation	02.03.04.008	-	-
Ventricular tachycardia	02.03.04.010	0.001468%
Vertigo	04.04.01.003; 17.02.12.002	-	-
Vision blurred	17.17.01.010; 06.02.06.007	0.000734%
Visual field defect	17.17.01.001; 06.02.07.003	-	-	Not Available
Visual impairment	06.02.10.013	0.001468%		Not Available
Vomiting	07.01.07.003	-	-
Mental status changes	19.07.01.001	0.000734%		Not Available
Tubulointerstitial nephritis	20.05.02.002	0.000734%		Not Available
Cardiotoxicity	02.11.01.009; 12.03.01.007	-	-	Not Available

The 6th Page First Pre 6 7 Next Last Total 7 Pages